We read with great interest the recent report by Ferruci et al 1 concerning the acute toxicities associated with autologous peripheral progenitor cell infusion in patients receiving high-dose chemotherapy. These authors reported a patient who developed an epileptiform seizure secondary to a vagal crisis during stem cell infusion. We observed the same type of side-effect in a patient treated in our unit.
We read with great interest the recent report by Ferruci et al 1 concerning the acute toxicities associated with autologous peripheral progenitor cell infusion in patients receiving high-dose chemotherapy. These authors reported a patient who developed an epileptiform seizure secondary to a vagal crisis during stem cell infusion. We observed the same type of side-effect in a patient treated in our unit.
The patient was a 53-year-old woman treated for myeloma. A partial response was obtained after three cycles of vincristine, adriamycin and dexamethasone. Peripheral blood stem cells (PBSC) were collected by leukapheresis (4.5 ϫ 10 6 CD34 ϩ /kg), washed to reduce the dimethylsulfoxide (DMSO) content, frozen and thawed for reinfusion 4 weeks later, after conditioning with high-dose melphalan (200 mg/m 2 ). During infusion of PBSC, which lasted 10 min, the patient developed nausea, vomiting and a tonicclonic generalized seizure which did not respond to two intravenous infusions of diazepam. During the fit, blood pressure and pulse were 160/80 mmHg and 90, respectively. This grand mal fit was complicated by prolonged loss of consciousness with global hypertonia and the patient required intubation ventilation for 48 h. After the seizure she developed prolonged paresis of the left arm. An EEG performed 3 h after the episode showed bilateral spike-andwave discharges. Levels of serum electrolytes (sodium, potassium, calcium, phosphate) measured a few minutes after the seizure were within normal limits. Microbial cultures of PBSC specimens were sterile. A CT scan of the brain was normal. With a follow-up of 12 months, the patient has had no further seizures.
For the 10 years during which we have performed almost 500 autologous stem cell transplants, this was the only case of an epileptic seizure occurring during stem cell infusion. As in the only other case described by Ferruci et al, 1 this tonic-clonic seizure might have been secondary to a vagal crisis since the patient had had nausea and vomiting during infusion and before the seizure. Epilepsy and encephalopathy have been described in patients receiving high-dose melphalan but these complications only occurred several days after high-dose chemotherapy in patients with severe renal failure treated with high-dose penicillin. 2 Our patient had no particular reason or predisposing factors for developing the tonic-clonic seizure. She had no previous history of epilepsy and there were no further seizures after the initial episode.
Some side-effects such as vagal responses may be due to the coldness of the freshly thawed infusate or to cryoprotectants such as DMSO.
3 Nausea and vomiting have been associated with DMSO and are alleviated by slowing the speed of infusion to reduce vagal hyperactivity. DMSO has also been implicated in patients who develop transient cardiac arrhythmias during peripheral blood stem cell infusion. 3 In this setting, DMSO has been reported to induce histamine release which can cause heart conduction block as well as allergic and gastrointestinal side-effects. 1 It is important to note, however, that the PBSC infused into our patient had been washed and contained very little DMSO.
In conclusion, although epileptic seizures occurring during stem cell infusion are rare, clinicians should be aware of this possible complication. The aetiology of this complication, including the role of DMSO, remains to be determined.
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